Stress-related regulation of the kynurenine pathway: Relevance to neuropsychiatric and degenerative disorders

Neuropharmacology

Volumn 112, Issue , 2017, Pages 307-323

  O'Farrell, Katherine ^a   Harkin, Andrew ^a  

^a TRINITY COLLEGE DUBLIN   (Ireland)

Author keywords

Inflammation; Kynurenine pathway; Neurodegenerative diseases; Psychiatric disorders; Stress

Indexed keywords

3 HYDROXYANTHRANILIC ACID; 3 HYDROXYKYNURENINE; ALLOPURINOL; AMISULPRIDE; CELECOXIB; CLENBUTEROL; CYCLIC AMP; CYCLIC AMP DEPENDENT PROTEIN KINASE; DICLOFENAC; FORMOTEROL; GAMMA INTERFERON; GLUTAMATE RECEPTOR; IMIDAZOLE; INDOLEAMINE 2,3 DIOXYGENASE; INDOMETACIN; INFLIXIMAB; INTERLEUKIN 1BETA; INTERLEUKIN 6; KAINIC ACID; KYNURENINE; MELOXICAM; NORADRENALIN; PARECOXIB; PF 04859989; TRIAZOLE; TRYPTOPHAN; TRYPTOPHAN 2,3 DIOXYGENASE; UNCLASSIFIED DRUG; XAMOTEROL;

ADJUVANT THERAPY; ANTIINFLAMMATORY ACTIVITY; BINDING AFFINITY; BRAIN DISEASE; CELL SURVIVAL; DEGENERATIVE DISEASE; ENZYME ACTIVITY; ENZYME INHIBITION; ENZYME SPECIFICITY; HUMAN; IN VITRO STUDY; IN VIVO STUDY; MENTAL DISEASE; NERVOUS SYSTEM INFLAMMATION; NEUROPROTECTION; NONHUMAN; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN METABOLISM; PROTEIN TARGETING; RESPIRATORY CHAIN; REVIEW; SCHIZOPHRENIA; STRESS; SYNAPTIC TRANSMISSION; TRYPTOPHAN METABOLISM; ANIMAL; MENTAL STRESS; METABOLISM; NEUROLOGIC DISEASE; PHYSIOLOGY;

ANIMALS; HUMANS; KYNURENINE; METABOLIC NETWORKS AND PATHWAYS; NERVOUS SYSTEM DISEASES; STRESS, PSYCHOLOGICAL;

EID: 84951320353     PISSN: 00283908     EISSN: 18737064     Source Type: Journal    
DOI: 10.1016/j.neuropharm.2015.12.004     Document Type: Review

References (229)

1. Agudelo, L.Z., Femenia, T., Orhan, F., Porsmyr-Palmertz, M., Goiny, M., Martinez-Redondo, V., Correia, J.C., Izadi, M., Bhat, M., Schuppe-Koistinen, I., Pettersson, A.T., Ferreira, D.M., Krook, A., Barres, R., Zierath, J.R., Erhardt, S., Lindskog, M., Ruas, J.L., Skeletal muscle PGC-1alpha1 modulates kynurenine metabolism and mediates resilience to stress-induced depression. Cell 159 (2014), 33–45.
2. Albelda, N., Joel, D., Animal models of obsessive-compulsive disorder: exploring pharmacology and neural substrates. Neurosci. Biobehav. Rev. 36 (2012), 47–63.
3. Alberati-Giani, D., Cesura, A.M., Broger, C., Warren, W.D., Röver, S., Malherbe, P., Cloning and functional expression of human kynurenine 3-monooxygenase. FEBS Lett. 410 (1997), 407–412.
4. Albuquerque, E.X., Schwarcz, R., Kynurenic acid as an antagonist of alpha7 nicotinic acetylcholine receptors in the brain: facts and challenges. Biochem. Pharmacol. 85 (2013), 1027–1032.
5. Amaral, M., Levy, C., Heyes, D.J., Lafite, P., Outeiro, T.F., Giorgini, F., Leys, D., Scrutton, N.S., Structural basis of kynurenine 3-monooxygenase inhibition. Nature 496 (2013), 382–385.
6. Anderson, G., Maes, M., TRYCAT pathways link peripheral inflammation, nicotine, somatization and depression in the etiology and course of Parkinson's disease. CNS Neurol. Disord. Drug Targets 13 (2014), 137–149.
7. Anderson, G., Rodriguez, M., Multiple sclerosis, seizures, and antiepileptics: role of IL-18, IDO, and melatonin. Eur. J. Neurol. 18 (2011), 680–685.
8. Asakura, M., Nagashima, H., Fujii, S., Sasuga, Y., Misonoh, A., Hasegawa, H., Osada, K., Influences of chronic stress on central nervous systems. Nihon Shinkei Seishin Yakurigaku Zasshi 20 (2000), 97–105.
9. Ball, H.J., Sanchez-Perez, A., Weiser, S., Austin, C.J., Astelbauer, F., Miu, J., Mcquillan, J.A., Stocker, R., Jermiin, L.S., Hunt, N.H., Characterization of an indoleamine 2,3-dioxygenase-like protein found in humans and mice. Gene 396 (2007), 203–213.
10. Ball, H.J., Jusof, F.F., Bakmiwewa, S.M., Hunt, N.H., Yuasa, H.J., Tryptophan-catabolizing enzymes – party of three. Front. Immunol., 5, 2014, 485.
11. Baran, H., Jellinger, K., Deecke, L., Kynurenine metabolism in Alzheimer's disease. J. Neural Transm. 106 (1999), 165–181.
12. Behan, W.M., Mcdonald, M., Darlington, L.G., Stone, T.W., Oxidative stress as a mechanism for quinolinic acid-induced hippocampal damage: protection by melatonin and deprenyl. Br. J. Pharmacol. 128 (1999), 1754–1760.
13. Berger, S.J., Sudar, D.C., Berger, N.A., Metabolic consequences of DNA damage: DNA damage induces alterations in glucose metabolism by activation of poly (ADP-ribose) polymerase. Biochem. Biophys. Res. Commun. 134 (1986), 227–232.
14. Berger, F., Ramirez-Hernandez, M.H., Ziegler, M., The new life of a centenarian: signalling functions of NAD(P). Trends Biochem. Sci. 29 (2004), 111–118.
15. Birch, P.J., Grossman, C.J., Hayes, A.G., Kynurenate and FG9041 have both competitive and non-competitive antagonist actions at excitatory amino acid receptors. Eur. J. Pharmacol. 151 (1988), 313–315.
16. Birch, P.J., Grossman, C.J., Hayes, A.G., Kynurenic acid antagonises responses to NMDA via an action at the strychnine-insensitive glycine receptor. Eur. J. Pharmacol. 154 (1988), 85–87.
17. Bohar, Z., Toldi, J., Fulop, F., Vecsei, L., Changing the face of kynurenines and neurotoxicity: therapeutic considerations. Int. J. Mol. Sci. 16 (2015), 9772–9793.
18. Bozza, S., Fallarino, F., Pitzurra, L., Zelante, T., Montagnoli, C., Bellocchio, S., Mosci, P., Vacca, C., Puccetti, P., Romani, L., A crucial role for tryptophan catabolism at the host/Candida albicans interface. J. Immunol. 174 (2005), 2910–2918.
19. Braidy, N., Grant, R., Adams, S., Brew, B.J., Guillemin, G.J., Mechanism for quinolinic acid cytotoxicity in human astrocytes and neurons. Neurotox. Res. 16 (2009), 77–86.
20. Braidy, N., Grant, R., Brew, B.J., Adams, S., Jayasena, T., Guillemin, G.J., Effects of kynurenine pathway metabolites on intracellular NAD synthesis and cell death in human primary astrocytes and neurons. Int. J. Tryptophan Res. 2 (2009), 61–69.
21. Bronte, V., Pittet, M.J., The spleen in local and systemic regulation of immunity. Immunity 39 (2013), 806–818.
22. Cazzullo, C.L., Sacchetti, E., Galluzzo, A., Panariello, A., Adorni, A., Pegoraro, M., Bosis, S., Colombo, F., Trabattoni, D., Zagliani, A., Clerici, M., Cytokine profiles in schizophrenic patients treated with risperidone: a 3-month follow-up study. Prog. Neuropsychopharmacol. Biol. Psychiatry 26 (2002), 33–39.
23. Chen, Y., Guillemin, G.J., Kynurenine pathway metabolites in humans: disease and healthy States. Int. J. Tryptophan Res. 2 (2009), 1–19.
24. Chen, Y. & Guillemin, G. 2012. The kynurenine pathway. In: Maure, M. (ed.). InTech.
25. Chen, Y., Brew, B.J., Guillemin, G.J., Characterization of the kynurenine pathway in NSC-34 cell line: implications for amyotrophic lateral sclerosis. J. Neurochem 118 (2011), 816–825.
26. Chiappelli, J., Pocivavsek, A., Nugent, K.L., Notarangelo, F.M., Kochunov, P., Rowland, L.M., Schwarcz, R., Hong, L.E., Stress-induced increase in kynurenic acid as a potential biomarker for patients with schizophrenia and distress intolerance. JAMA Psychiatry 71 (2014), 761–768.
27. Chiarugi, A., Carpenedo, R., Moroni, F., Kynurenine disposition in blood and brain of mice: effects of selective inhibitors of kynurenine hydroxylase and of kynureninase. J. Neurochem. 67 (1996), 692–698.
28. Chiarugi, A., Dello Sbarba, P., Paccagnini, A., Donnini, S., Filippi, S., Moroni, F., Combined inhibition of indoleamine 2,3-dioxygenase and nitric oxide synthase modulates neurotoxin release by interferon-gamma-activated macrophages. J. Leukoc. Biol. 68 (2000), 260–266.
29. Chiarugi, A., Cozzi, A., Ballerini, C., Massacesi, L., Moroni, F., Kynurenine 3-mono-oxygenase activity and neurotoxic kynurenine metabolites increase in the spinal cord of rats with experimental allergic encephalomyelitis. Neuroscience 102 (2001), 687–695.
30. Chiba, S., Numakawa, T., Ninomiya, M., Richards, M.C., Wakabayashi, C., Kunugi, H., Chronic restraint stress causes anxiety- and depression-like behaviors, downregulates glucocorticoid receptor expression, and attenuates glutamate release induced by brain-derived neurotrophic factor in the prefrontal cortex. Prog. Neuropsychopharmacol. Biol. Psychiatry 39 (2012), 112–119.
31. Comings, D.E., Clinical and molecular genetics of ADHD and Tourette syndrome. Two related polygenic disorders. Ann. N. Y. Acad. Sci. 931 (2001), 50–83.
32. Connor, T.J., Starr, N., O'Sullivan, J.B., Harkin, A., Induction of indolamine 2,3-dioxygenase and kynurenine 3-monooxygenase in rat brain following a systemic inflammatory challenge: a role for IFN-gamma?. Neurosci. Lett. 441 (2008), 29–34.
33. Cuartero, M.I., Ballesteros, I., de la Parra, J., Harkin, A.L., Abautret-Daly, A., Sherwin, E., Fernandez-Salguero, P., Corbi, A.L., Lizasoain, I., Moro, M.A., L-kynurenine/aryl hydrocarbon receptor pathway mediates brain damage after experimental stroke. Circulation 130 (2014), 2040–2051.
34. Curzon, G., Green, A.R., Effects of immobilization on rat liver tryptophan pyrrolase and brain 5-hydroxytryptamine metabolism. Br. J. Pharmacol. 37 (1969), 689–697.
35. Cutler, J.A., Rush, A.J., Mcmahon, F.J., Laje, G., Common genetic variation in the indoleamine-2,3-dioxygenase genes and antidepressant treatment outcome in major depressive disorder. J. Psychopharmacol. 26 (2012), 360–367.
36. Darlington, L.G., Mackay, G.M., Forrest, C.M., Stoy, N., George, C., Stone, T.W., Altered kynurenine metabolism correlates with infarct volume in stroke. Eur. J. Neurosci. 26 (2007), 2211–2221.
37. Deacon, R.M., The successive alleys test of anxiety in mice and rats. J. Vis. Exp.(76), 2013.
38. Dickerson, F.B., Stallings, C.R., Origoni, A.E., Sullens, A., Khushalani, S., Sandson, N., Yolken, R.H., A double-blind trial of adjunctive allopurinol for schizophrenia. Schizophr. Res. 109 (2009), 66–69.
39. Divorty, N., Mackenzie, A.E., Nicklin, S.A., Milligan, G., G protein-coupled receptor 35: an emerging target in inflammatory and cardiovascular disease. Front. Pharmacol., 6, 2015, 41.
40. Dolusic, E., Larrieu, P., Moineaux, L., Stroobant, V., Pilotte, L., Colau, D., Pochet, L., Van den Eynde, B., Masereel, B., Wouters, J., Frederick, R., Tryptophan 2,3-dioxygenase (TDO) inhibitors. 3-(2-(pyridyl)ethenyl)indoles as potential anticancer immunomodulators. J. Med. Chem. 54 (2011), 5320–5334.
41. Dong, Y., Poellinger, L., Gustafsson, J.A., Okret, S., Regulation of glucocorticoid receptor expression: evidence for transcriptional and posttranslational mechanisms. Mol. Endocrinol. 2 (1988), 1256–1264.
42. Dong-Ryul, L., Kondo, H., Furukawa, S., Nakano, K., Stimulation of NGF production by tryptophan and its metabolites in cultured mouse astroglial cells. Brain Res. 777 (1997), 228–230.
43. Dounay, A.B., Anderson, M., Bechle, B.M., Campbell, B.M., Claffey, M.M., Evdokimov, A., Evrard, E., Fonseca, K.R., Gan, X., Ghosh, S., Hayward, M.M., Horner, W., Kim, J.Y., Mcallister, L.A., Pandit, J., Paradis, V., Parikh, V.D., Reese, M.R., Rong, S., Salafia, M.A., Schuyten, K., Strick, C.A., Tuttle, J.B., Valentine, J., Wang, H., Zawadzke, L.E., Verhoest, P.R., Discovery of brain-penetrant, irreversible kynurenine aminotransferase II inhibitors for schizophrenia. ACS Med. Chem. Lett. 3 (2012), 187–192.
44. Dounay, A.B., Tuttle, J.B., Verhoest, P.R., Challenges and opportunities in the discovery of new therapeutics targeting the kynurenine pathway. J. Med. Chem. 58:22 (2015), 8762–8782.
45. Dunn, A.J., Swiergiel, A.H., de Beaurepaire, R., Cytokines as mediators of depression: what can we learn from animal studies?. Neurosci. Biobehav. Rev. 29 (2005), 891–909.
46. Elenkov, I.J., Wilder, R.L., Chrousos, G.P., Vizi, E.S., The sympathetic nerve–an integrative interface between two supersystems: the brain and the immune system. Pharmacol. Rev. 52 (2000), 595–638.
47. Erhardt, S., Engberg, G., Increased phasic activity of dopaminergic neurones in the rat ventral tegmental area following pharmacologically elevated levels of endogenous kynurenic acid. Acta Physiol. Scand. 175 (2002), 45–53.
48. 2O during hydroxylation of L-[3,5-3H]kynurenine. Anal. Biochem. 205 (1992), 257–262.
49. Esch, T., Stefano, G.B., Fricchione, G.L., Benson, H., The role of stress in neurodegenerative diseases and mental disorders. Neuro Endocrinol. Lett. 23 (2002), 199–208.
50. Fallarino, F., Grohmann, U., Vacca, C., Bianchi, R., Orabona, C., Spreca, A., Fioretti, M.C., Puccetti, P., T cell apoptosis by tryptophan catabolism. Cell Death Differ. 9 (2002), 1069–1077.
51. Faravelli, C., Lo Sauro, C., Godini, L., Lelli, L., Benni, L., Pietrini, F., Lazzeretti, L., Talamba, G.A., Fioravanti, G., Ricca, V., Childhood stressful events, HPA axis and anxiety disorders. World J. Psychiatry 2 (2012), 13–25.
52. Fatokun, A.A., Hunt, N.H., Ball, H.J., Indoleamine 2,3-dioxygenase 2 (IDO2) and the kynurenine pathway: characteristics and potential roles in health and disease. Amino Acids 45 (2013), 1319–1329.
53. Federico, A., Cardaioli, E., Da Pozzo, P., Formichi, P., Gallus, G.N., Radi, E., Mitochondria, oxidative stress and neurodegeneration. J. Neurol. Sci. 322 (2012), 254–262.
54. Ferrante, M., Migliore, M., Ascoli, G.A., Functional impact of dendritic branch-point morphology. J. Neurosci. 33 (2013), 2156–2165.
55. Forouhar, F., Anderson, J.L., Mowat, C.G., Vorobiev, S.M., Hussain, A., Abashidze, M., Bruckmann, C., Thackray, S.J., Seetharaman, J., Tucker, T., Xiao, R., Ma, L.C., Zhao, L., Acton, T.B., Montelione, G.T., Chapman, S.K., Tong, L., Molecular insights into substrate recognition and catalysis by tryptophan 2,3-dioxygenase. Proc. Natl. Acad. Sci. U. S. A. 104 (2007), 473–478.
56. Forrest, C.M., Mackay, G.M., Stoy, N., Egerton, M., Christofides, J., Stone, T.W., Darlington, L.G., Tryptophan loading induces oxidative stress. Free Radic. Res. 38 (2004), 1167–1171.
57. Forrest, C.M., Khalil, O.S., Pisar, M., Darlington, L.G., Stone, T.W., Prenatal inhibition of the tryptophan-kynurenine pathway alters synaptic plasticity and protein expression in the rat hippocampus. Brain Res. 1504 (2013), 1–15.
58. Forrest, C.M., Khalil, O.S., Pisar, M., Mcnair, K., Kornisiuk, E., Snitcofsky, M., Gonzalez, N., Jerusalinsky, D., Darlington, L.G., Stone, T.W., Changes in synaptic transmission and protein expression in the brains of adult offspring after prenatal inhibition of the kynurenine pathway. Neuroscience 254 (2013), 241–259.
59. Fukuda, K., Etiological classification of depression based on the enzymes of tryptophan metabolism. BMC Psychiatry, 14, 2014, 372.
60. Fukui, S., Schwarcz, R., Rapoport, S.I., Takada, Y., Smith, Q.R., Blood-brain barrier transport of kynurenines: implications for brain synthesis and metabolism. J. Neurochem. 56 (1991), 2007–2017.
61. Fukunaga, M., Yamamoto, Y., Kawasoe, M., Arioka, Y., Murakami, Y., Hoshi, M., Saito, K., Studies on tissue and cellular distribution of indoleamine 2,3-dioxygenase 2: the absence of IDO1 upregulates IDO2 expression in the epididymis. J. Histochem. Cytochem. 60 (2012), 854–860.
62. Funakoshi, Masaaki, K., Toshikazu, N., Modulation of tryptophan metabolism, promotion of neurogenesis and alteration of anxiety-related behavior in tryptophan 2,3-dioxygenase-deficient mice. Int. J. Tryptophan Res., 7, 2011.
63. Funakoshi, H., Kanai, M., Nakamura, T., Modulation of tryptophan metabolism, pomotion of neurogenesis and alteration of anxiety-related behavior in tryptophan 2,3-dioxygenase-deficient mice. Int. J. Tryptophan Res. IJTR 4 (2011), 7–18.
64. Furtado, M., Katzman, M.A., Neuroinflammatory pathways in anxiety, posttraumatic stress, and obsessive compulsive disorders. Psychiatry Res. 229 (2015), 37–48.
65. Gallowitsch-Puerta, M., Tracey, K.J., Immunologic role of the cholinergic anti-inflammatory pathway and the nicotinic acetylcholine alpha 7 receptor. Ann. N. Y. Acad. Sci. 1062 (2005), 209–219.
66. Gaspar, P., Cases, O., Maroteaux, L., The developmental role of serotonin: news from mouse molecular genetics. Nat. Rev. Neurosci. 4 (2003), 1002–1012.
67. Gibney, S.M., Mcguinness, B., Prendergast, C., Harkin, A., Connor, T.J., Poly I: C-induced activation of the immune response is accompanied by depression and anxiety-like behaviours, kynurenine pathway activation and reduced BDNF expression. Brain Behav. Immun. 28 (2013), 170–181.
68. Gibney, S.M., Fagan, E.M., Waldron, A.M., O'Byrne, J., Connor, T.J., Harkin, A., Inhibition of stress-induced hepatic tryptophan 2,3-dioxygenase exhibits antidepressant activity in an animal model of depressive behaviour. Int. J. Neuropsychopharmacol. 17 (2014), 917–928.
69. Gigler, G., Szenasi, G., Simo, A., Levay, G., Harsing, L.G. Jr., Sas, K., Vecsei, L., Toldi, J., Neuroprotective effect of L-kynurenine sulfate administered before focal cerebral ischemia in mice and global cerebral ischemia in gerbils. Eur. J. Pharmacol. 564 (2007), 116–122.
70. Glass, C.K., Saijo, K., Winner, B., Marchetto, M.C., Gage, F.H., Mechanisms underlying inflammation in neurodegeneration. Cell 140 (2010), 918–934.
71. Gleeson, L.C., Ryan, K.J., Griffin, E.W., Connor, T.J., Harkin, A., The beta2-adrenoceptor agonist clenbuterol elicits neuroprotective, anti-inflammatory and neurotrophic actions in the kainic acid model of excitotoxicity. Brain Behav. Immun. 24 (2010), 1354–1361.
72. Goswami, S., Rodriguez-Sierra, O., Cascardi, M., Pare, D., Animal models of post-traumatic stress disorder: face validity. Front. Neurosci., 7, 2013, 89.
73. Gracia-Rubio, I., Moscoso-Castro, M., Pozo, O.J., Marcos, J., Nadal, R., Valverde, O., Maternal separation induces neuroinflammation and long-lasting emotional alterations in mice. Prog. Neuropsychopharmacol. Biol. Psychiatry 65 (2015), 104–117.
74. Gray, S.M., Bloch, M.H., Systematic review of proinflammatory cytokines in obsessive-compulsive disorder. Curr. Psychiatry Rep. 14 (2012), 220–228.
75. Green, A.R., Curzon, G., Decrease of 5-hydroxytryptamine in the brain provoked by hydrocortisone and its prevention by allopurinol. Nature 220 (1968), 1095–1097.
76. Green, A.R., Curzon, G., Effects of hydrocortisone and immobilization on tryptophan metabolism in brain and liver of rats of different ages. Biochem. Pharmacol. 24 (1975), 713–716.
77. Green, A.R., Woods, H.F., Joseph, M.H., Tryptophan metabolism in the isolated perfused liver of the rat: effects of tryptophan concentration, hydrocortisone and allopurinol on tryptophan pyrrolase activity and kynurenine formation. Br. J. Pharmacol. 57 (1976), 103–114.
78. Gregoire, L., Rassoulpour, A., Guidetti, P., Samadi, P., Bedard, P.J., Izzo, E., Schwarcz, R., Di Paolo, T., Prolonged kynurenine 3-hydroxylase inhibition reduces development of levodopa-induced dyskinesias in parkinsonian monkeys. Behav. Brain Res. 186 (2008), 161–167.
79. Guidetti, P., Schwarcz, R., 3-Hydroxykynurenine and quinolinate: pathogenic synergism in early grade Huntington's disease?. Adv. Exp. Med. Biol. 527 (2003), 137–145.
80. Guidetti, P., Reddy, P.H., Tagle, D.A., Schwarcz, R., Early kynurenergic impairment in Huntington's disease and in a transgenic animal model. Neurosci. Lett. 283 (2000), 233–235.
81. Guidetti, P., Luthi-Carter, R.E., Augood, S.J., Schwarcz, R., Neostriatal and cortical quinolinate levels are increased in early grade Huntington's disease. Neurobiol. Dis. 17 (2004), 455–461.
82. Guillemin, G.J., Quinolinic acid, the inescapable neurotoxin. FEBS J. 279 (2012), 1356–1365.
83. Guillemin, G.J., Brew, B.J., Implications of the kynurenine pathway and quinolinic acid in Alzheimer's disease. Redox Rep. 7 (2002), 199–206.
84. Guillemin, G.J., Kerr, S.J., Smythe, G.A., Smith, D.G., Kapoor, V., Armati, P.J., Croitoru, J., Brew, B.J., Kynurenine pathway metabolism in human astrocytes: a paradox for neuronal protection. J. Neurochem. 78 (2001), 842–853.
85. Guillemin, G.J., Smith, D.G., Smythe, G.A., Armati, P.J., Brew, B.J., Expression of the kynurenine pathway enzymes in human microglia and macrophages. Adv. Exp. Med. Biol. 527 (2003), 105–112.
86. Guillemin, G.J., Smythe, G.A., Veas, L.A., Takikawa, O., Brew, B.J., A beta 1-42 induces production of quinolinic acid by human macrophages and microglia. Neuroreport 14 (2003), 2311–2315.
87. Guillemin, G.J., Kerr, S.J., Brew, B.J., Involvement of quinolinic acid in AIDS dementia complex. Neurotox. Res. 7 (2005), 103–123.
88. Guillemin, G.J., Smythe, G., Takikawa, O., Brew, B.J., Expression of indoleamine 2,3-dioxygenase and production of quinolinic acid by human microglia, astrocytes, and neurons. Glia 49 (2005), 15–23.
89. Guillemin, G.J., Cullen, K.M., Lim, C.K., Smythe, G.A., Garner, B., Kapoor, V., Takikawa, O., Brew, B.J., Characterization of the kynurenine pathway in human neurons. J. Neurosci. 27 (2007), 12884–12892.
90. Haroon, E., Raison, C.L., Miller, A.H., Psychoneuroimmunology meets neuropsychopharmacology: translational implications of the impact of inflammation on behavior. Neuropsychopharmacology 37 (2012), 137–162.
91. Heisler, J.M., O'Connor, J.C., Indoleamine 2,3-dioxygenase-dependent neurotoxic kynurenine metabolism mediates inflammation-induced deficit in recognition memory. Brain Behav. Immun. 50 (2015), 115–124.
92. Heyes, M.P., Achim, C.L., Wiley, C.A., Major, E.O., Saito, K., Markey, S.P., Human microglia convert l-tryptophan into the neurotoxin quinolinic acid. Biochem. J. 320:Pt 2 (1996), 595–597.
93. Hill, M., Tanguy-Royer, S., Royer, P., Chauveau, C., Asghar, K., Tesson, L., Lavainne, F., Remy, S., Brion, R., Hubert, F.X., Heslan, M., Rimbert, M., Berthelot, L., Moffett, J.R., Josien, R., Gregoire, M., Anegon, I., IDO expands human CD4+CD25high regulatory T cells by promoting maturation of LPS-treated dendritic cells. Eur. J. Immunol. 37 (2007), 3054–3062.
94. Hilmas, C., Pereira, E.F., Alkondon, M., Rassoulpour, A., Schwarcz, R., Albuquerque, E.X., The brain metabolite kynurenic acid inhibits alpha7 nicotinic receptor activity and increases non-alpha7 nicotinic receptor expression: physiopathological implications. J. Neurosci. 21 (2001), 7463–7473.
95. Holtzman, C.W., Trotman, H.D., Goulding, S.M., Ryan, A.T., Macdonald, A.N., Shapiro, D.I., Brasfield, J.L., Walker, E.F., Stress and neurodevelopmental processes in the emergence of psychosis. Neuroscience 249 (2013), 172–191.
96. Hou, D.Y., Muller, A.J., Sharma, M.D., Duhadaway, J., Banerjee, T., Johnson, M., Mellor, A.L., Prendergast, G.C., Munn, D.H., Inhibition of indoleamine 2,3-dioxygenase in dendritic cells by stereoisomers of 1-methyl-tryptophan correlates with antitumor responses. Cancer Res. 67 (2007), 792–801.
97. Hwu, P., Du, M.X., Lapointe, R., Do, M., Taylor, M.W., Young, H.A., Indoleamine 2,3-dioxygenase production by human dendritic cells results in the inhibition of T cell proliferation. J. Immunol. 164 (2000), 3596–3599.
98. Javitt, D.C., Zukin, S.R., Recent advances in the phencyclidine model of schizophrenia. Am. J. Psychiatry 148 (1991), 1301–1308.
99. Jenkins, L., Alvarez-Curto, E., Campbell, K., de Munnik, S., Canals, M., Schlyer, S., Milligan, G., Agonist activation of the G protein-coupled receptor GPR35 involves transmembrane domain III and is transduced via Galpha(1)(3) and beta-arrestin-2. Br. J. Pharmacol. 162 (2011), 733–748.
100. Johnson, P.L., Shekhar, A., An animal model of panic vulnerability with chronic disinhibition of the dorsomedial/perifornical hypothalamus. Physiol. Behav. 107 (2012), 686–698.
101. Jones, S.P., Franco, N.F., Varney, B., Sundaram, G., Brown, D.A., de Bie, J., Lim, C.K., Guillemin, G.J., Brew, B.J., Expression of the kynurenine pathway in human peripheral blood mononuclear cells: implications for inflammatory and neurodegenerative disease. PLoS One, 10, 2015, e0131389.
102. Kanai, M., Funakoshi, H., Takahashi, H., Hayakawa, T., Mizuno, S., Matsumoto, K., Nakamura, T., Tryptophan 2,3-dioxygenase is a key modulator of physiological neurogenesis and anxiety-related behavior in mice. Mol. Brain, 2, 2009, 8.
103. Kanai, M., Nakamura, T., Funakoshi, H., Identification and characterization of novel variants of the tryptophan 2,3-dioxygenase gene: differential regulation in the mouse nervous system during development. Neurosci. Res. 64 (2009), 111–117.
104. Kanai, M., Funakoshi, H., Nakamura, T., Implication of tryptophan 2,3-dioxygenase and its novel variants in the hippocampus and cerebellum during the developing and adult brain. Int. J. Tryptophan Res. IJTR 3 (2010), 141–149.
105. Karakuła-Juchnowicz, H., Flis, M., Szymona, K., Kuczyńska, M., Stelmach, E., Kowal-Popczak, A., New prospects for antipsychotic treatment – the role of the kynurenine pathway. Psychiatry Pol. 48 (2015), 1167–1177.
106. Kerr, S.J., Armati, P.J., Guillemin, G.J., Brew, B.J., Chronic exposure of human neurons to quinolinic acid results in neuronal changes consistent with AIDS dementia complex. Aids 12 (1998), 355–363.
107. Khalil, O.S., Pisar, M., Forrest, C.M., Vincenten, M.C.J., Darlington, L.G., Stone, T.W., Prenatal inhibition of the kynurenine pathway leads to structural changes in the hippocampus of adult rat offspring. Eur. J. Neurosci. 39 (2014), 1558–1571.
108. Kim, Y.K., Myint, A.M., Verkerk, R., Scharpe, S., Steinbusch, H., Leonard, B., Cytokine changes and tryptophan metabolites in medication-naive and medication-free schizophrenic patients. Neuropsychobiology 59 (2009), 123–129.
109. Kim, J., Hong, H., Heo, A., Park, W., Indole toxicity involves the inhibition of adenosine triphosphate production and protein folding in Pseudomonas putida. FEMS Microbiol. Lett. 343 (2013), 89–99.
110. Knyihar-Csillik, E., Csillik, B., Pakaski, M., Krisztin-Peva, B., Dobo, E., Okuno, E., Vecsei, L., Decreased expression of kynurenine aminotransferase-I (KAT-I) in the substantia nigra of mice after 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) treatment. Neuroscience 126 (2004), 899–914.
111. Kocki, T., Luchowski, P., Luchowska, E., Wielosz, M., Turski, W.A., Urbanska, E.M., L-cysteine sulphinate, endogenous sulphur-containing amino acid, inhibits rat brain kynurenic acid production via selective interference with kynurenine aminotransferase II. Neurosci. Lett. 346 (2003), 97–100.
112. Koenig, J.I., Kirkpatrick, B., Lee, P., Glucocorticoid hormones and early brain development in schizophrenia. Neuropsychopharmacology 27 (2002), 309–318.
113. Kohm, A.P., Sanders, V.M., Norepinephrine and beta 2-adrenergic receptor stimulation regulate CD4+ T and B lymphocyte function in vitro and in vivo. Pharmacol. Rev. 53 (2001), 487–525.
114. Koshy Cherian, A., Gritton, H., Johnson, D.E., Young, D., Kozak, R., Sarter, M., A systemically-available kynurenine aminotransferase II (KAT II) inhibitor restores nicotine-evoked glutamatergic activity in the cortex of rats. Neuropharmacology 82 (2014), 41–48.
115. Krystal, J.H., Karper, L.P., Seibyl, J.P., Freeman, G.K., Delaney, R., Bremner, J.D., Heninger, G.R., Bowers, M.B. Jr., Charney, D.S., Subanesthetic effects of the noncompetitive NMDA antagonist, ketamine, in humans. Psychotomimetic, perceptual, cognitive, and neuroendocrine responses. Arch. Gen. Psychiatry 51 (1994), 199–214.
116. Kubesova, A., Tejkalova, H., Syslova, K., Kacer, P., Vondrousova, J., Tyls, F., Fujakova, M., Palenicek, T., Horacek, J., Biochemical, histopathological and morphological profiling of a rat model of early immune stimulation: relation to psychopathology. PLoS One, 10, 2015, e0115439.
117. Kwidzinski, E., Bechmann, I., IDO expression in the brain: a double-edged sword. J. Mol. Med. (Berl.) 85 (2007), 1351–1359.
118. Lauder, J.M., Ontogeny of the serotonergic system in the rat: serotonin as a developmental signal. Ann. N. Y. Acad. Sci. 600 (1990), 297–313 discussion 314.
119. Laugeray, A., Launay, J.M., Callebert, J., Surget, A., Belzung, C., Barone, P.R., Evidence for a key role of the peripheral kynurenine pathway in the modulation of anxiety- and depression-like behaviours in mice: focus on individual differences. Pharmacol. Biochem. Behav. 98 (2011), 161–168.
120. Lawson, M.A., Parrott, J.M., Mccusker, R.H., Dantzer, R., Kelley, K.W., O'Connor, J.C., Intracerebroventricular administration of lipopolysaccharide induces indoleamine-2,3-dioxygenase-dependent depression-like behaviors. J. Neuroinflamm., 10, 2013, 87.
121. Lim, C.K., Brew, B.J., Sundaram, G., Guillemin, G.J., Understanding the roles of the kynurenine pathway in multiple sclerosis progression. Int. J. Tryptophan Res. 3 (2010), 157–167.
122. Linden, N., Onwuanibe, A., Sandson, N., Rapid resolution of psychotic symptoms in a patient with schizophrenia using allopurinol as an adjuvant: a case report. Clin. Schizophr. Relat. Psychoses 7 (2014), 231–234.
123. Lob, S., Konigsrainer, A., Schafer, R., Rammensee, H.G., Opelz, G., Terness, P., Levo- but not dextro-1-methyl tryptophan abrogates the IDO activity of human dendritic cells. Blood 111 (2008), 2152–2154.
124. Lopresti, A.L., Maker, G.L., Hood, S.D., Drummond, P.D., A review of peripheral biomarkers in major depression: the potential of inflammatory and oxidative stress biomarkers. Prog. Neuropsychopharmacol. Biol. Psychiatry 48 (2014), 102–111.
125. Lucassen, P.J., Naninck, E.F., van Goudoever, J.B., Fitzsimons, C., Joels, M., Korosi, A., Perinatal programming of adult hippocampal structure and function; emerging roles of stress, nutrition and epigenetics. Trends Neurosci. 36 (2013), 621–631.
126. Luchowska, E., Kloc, R., Olajossy, B., Wnuk, S., Wielosz, M., Owe-Larsson, B., Urbanska, E.M., beta-adrenergic enhancement of brain kynurenic acid production mediated via cAMP-related protein kinase A signaling. Prog. Neuropsychopharmacol. Biol. Psychiatry 33 (2009), 519–529.
127. Luchowski, P., Luchowska, E., Turski, W.A., Urbanska, E.M., 1-Methyl-4-phenylpyridinium and 3-nitropropionic acid diminish cortical synthesis of kynurenic acid via interference with kynurenine aminotransferases in rats. Neurosci. Lett. 330 (2002), 49–52.
128. Lugo-Huitron, R., Ugalde Muniz, P., Pineda, B., Pedraza-Chaverri, J., Rios, C., Perez-de la Cruz, V., Quinolinic acid: an endogenous neurotoxin with multiple targets. Oxid. Med. Cell. Longev., 2013, 2013, 104024.
129. Maddison, D.C., Giorgini, F., The kynurenine pathway and neurodegenerative disease. Semin. Cell Dev. Biol. 40 (2015), 134–141.
130. Madge, D., Hazelwood, R., Iyer, R., Jones, H., Salter, M., Novel tryptophan dioxygenase inhibitors and combined tryptophan dioxygenase/5-HT reuptake inhibitors. Bioorg. Med. Chem. Lett. 6 (1996), 857–860.
131. Maes, M., Depression is an inflammatory disease, but cell-mediated immune activation is the key component of depression. Prog. Neuropsychopharmacol. Biol. Psychiatry 35 (2011), 664–675.
132. Maes, M., Verkerk, R., Bonaccorso, S., Ombelet, W., Bosmans, E., Scharpe, S., Depressive and anxiety symptoms in the early puerperium are related to increased degradation of tryptophan into kynurenine, a phenomenon which is related to immune activation. Life Sci. 71 (2002), 1837–1848.
133. Maes, M., Leonard, B.E., Myint, A.M., Kubera, M., Verkerk, R., The new '5-HT' hypothesis of depression: cell-mediated immune activation induces indoleamine 2,3-dioxygenase, which leads to lower plasma tryptophan and an increased synthesis of detrimental tryptophan catabolites (TRYCATs), both of which contribute to the onset of depression. Prog. Neuropsychopharmacol. Biol. Psychiatry 35 (2011), 702–721.
134. Maisel, A.S., Fowler, P., Rearden, A., Motulsky, H.J., Michel, M.C., A new method for isolation of human lymphocyte subsets reveals differential regulation of beta-adrenergic receptors by terbutaline treatment. Clin. Pharmacol. Ther. 46 (1989), 429–439.
135. Marchi, M., Risso, F., Viola, C., Cavazzani, P., Raiteri, M., Direct evidence that release-stimulating alpha7* nicotinic cholinergic receptors are localized on human and rat brain glutamatergic axon terminals. J. Neurochem. 80 (2002), 1071–1078.
136. Marques, A.H., Silverman, M.N., Sternberg, E.M., Glucocorticoid dysregulations and their clinical correlates. From receptors to therapeutics. Ann. N. Y. Acad. Sci. 1179 (2009), 1–18.
137. Marti-Masso, J.F., Bergareche, A., Makarov, V., Ruiz-Martinez, J., Gorostidi, A., Lopez de Munain, A., Poza, J.J., Striano, P., Buxbaum, J.D., Paisan-Ruiz, C., The ACMSD gene, involved in tryptophan metabolism, is mutated in a family with cortical myoclonus, epilepsy, and parkinsonism. J. Mol. Med. (Berl.) 91 (2013), 1399–1406.
138. Martin, D., Thompson, M.A., Nadler, J.V., The neuroprotective agent riluzole inhibits release of glutamate and aspartate from slices of hippocampal area CA1. Eur. J. Pharmacol. 250 (1993), 473–476.
139. McEwen, B.S., Understanding the potency of stressful early life experiences on brain and body function. Metab. Clin. Exp. 57 (2008), S11–S15.
140. Miller, C.L., Llenos, I.C., Dulay, J.R., Barillo, M.M., Yolken, R.H., Weis, S., Expression of the kynurenine pathway enzyme tryptophan 2,3-dioxygenase is increased in the frontal cortex of individuals with schizophrenia. Neurobiol. Dis. 15 (2004), 618–629.
141. Miller, G.E., Chen, E., Sze, J., Marin, T., Arevalo, J.M., Doll, R., Ma, R., Cole, S.W., A functional genomic fingerprint of chronic stress in humans: blunted glucocorticoid and increased NF-kappaB signaling. Biol. Psychiatry 64 (2008), 266–272.
142. Miranda, A.F., Boegman, R.J., Beninger, R.J., Jhamandas, K., Protection against quinolinic acid-mediated excitotoxicity in nigrostriatal dopaminergic neurons by endogenous kynurenic acid. Neuroscience 78 (1997), 967–975.
143. Moroni, F., Russi, P., Lombardi, G., Beni, M., Carla, V., Presence of kynurenic acid in the mammalian brain. J. Neurochem. 51 (1988), 177–180.
144. Muller, N., The role of anti-inflammatory treatment in psychiatric disorders. Psychiatr. Danub. 25 (2013), 292–298.
145. Muller, N., Schwarz, M.J., Immune system and schizophrenia. Curr. Immunol. Rev. 6 (2010), 213–220.
146. Muller, N., Krause, D., Dehning, S., Musil, R., Schennach-Wolff, R., Obermeier, M., Moller, H.J., Klauss, V., Schwarz, M.J., Riedel, M., Celecoxib treatment in an early stage of schizophrenia: results of a randomized, double-blind, placebo-controlled trial of celecoxib augmentation of amisulpride treatment. Schizophr. Res. 121 (2010), 118–124.
147. Munn, D.H., Indoleamine 2,3-dioxygenase, Tregs and cancer. Curr. Med. Chem. 18 (2011), 2240–2246.
148. Myint, A.M., Kim, Y.K., Cytokine–serotonin interaction through IDO: a neurodegeneration hypothesis of depression. Med. Hypotheses 61 (2003), 519–525.
149. Myint, A.M., Kim, Y.K., Network beyond IDO in psychiatric disorders: revisiting neurodegeneration hypothesis. Prog. Neuropsychopharmacol. Biol. Psychiatry 48 (2014), 304–313.
150. Myint, A.M., Kim, Y.K., Verkerk, R., Scharpe, S., Steinbusch, H., Leonard, B., Kynurenine pathway in major depression: evidence of impaired neuroprotection. J. Affect Disord. 98 (2007), 143–151.
151. Myint, A.M., Schwarz, M.J., Verkerk, R., Mueller, H.H., Zach, J., Scharpe, S., Steinbusch, H.W., Leonard, B.E., Kim, Y.K., Reversal of imbalance between kynurenic acid and 3-hydroxykynurenine by antipsychotics in medication-naive and medication-free schizophrenic patients. Brain Behav. Immun. 25 (2011), 1576–1581.
152. Nabi, R., Serajee, F.J., Chugani, D.C., Zhong, H., Huq, A.H., Association of tryptophan 2,3 dioxygenase gene polymorphism with autism. Am. J. Med. Genet. B Neuropsychiatr. Genet. 125B (2004), 63–68.
153. Najjar, S., Pearlman, D.M., Alper, K., Najjar, A., Devinsky, O., Neuroinflammation and psychiatric illness. J. Neuroinflamm., 10, 2013, 43.
154. Nemeth, H., Robotka, H., Kis, Z., Rozsa, E., Janaky, T., Somlai, C., Marosi, M., Farkas, T., Toldi, J., Vecsei, L., Kynurenine administered together with probenecid markedly inhibits pentylenetetrazol-induced seizures. An electrophysiological and behavioural study. Neuropharmacology 47 (2004), 916–925.
155. Nemeth, H., Toldi, J., Vecsei, L., Kynurenines, Parkinson's disease and other neurodegenerative disorders: preclinical and clinical studies. J. Neural Transm. Suppl., 2006, 285–304.
156. Nikkheslat, N., Zunszain, P.A., Horowitz, M.A., Barbosa, I.G., Parker, J.A., Myint, A.M., Schwarz, M.J., Tylee, A.T., Carvalho, L.A., Pariante, C.M., Insufficient glucocorticoid signaling and elevated inflammation in coronary heart disease patients with comorbid depression. Brain Behav. Immun. 48 (2015), 8–18.
157. O'Connor, J.C., Lawson, M.A., Andre, C., Moreau, M., Lestage, J., Castanon, N., Kelley, K.W., Dantzer, R., Lipopolysaccharide-induced depressive-like behavior is mediated by indoleamine 2,3-dioxygenase activation in mice. Mol. Psychiatry 14 (2009), 511–522.
158. Ogawa, T., Matson, W.R., Beal, M.F., Myers, R.H., Bird, E.D., Milbury, P., Saso, S., Kynurenine pathway abnormalities in Parkinson's disease. Neurology 42 (1992), 1702–1706.
159. Okuda, S., Nishiyama, N., Saito, H., Katsuki, H., Hydrogen peroxide-mediated neuronal cell death induced by an endogenous neurotoxin, 3-hydroxykynurenine. Proc. Natl. Acad. Sci. U. S. A. 93 (1996), 12553–12558.
160. Okuda, S., Nishiyama, N., Saito, H., Katsuki, H., 3-Hydroxykynurenine, an endogenous oxidative stress generator, causes neuronal cell death with apoptotic features and region selectivity. J. Neurochem. 70 (1998), 299–307.
161. Opitz, C.A., Litzenburger, U.M., Sahm, F., Ott, M., Tritschler, I., Trump, S., Schumacher, T., Jestaedt, L., Schrenk, D., Weller, M., Jugold, M., Guillemin, G.J., Miller, C.L., Lutz, C., Radlwimmer, B., Lehmann, I., von Deimling, A., Wick, W., Platten, M., An endogenous tumour-promoting ligand of the human aryl hydrocarbon receptor. Nature 478 (2011), 197–203.
162. Oxenkrug, G.F., Tryptophan–kynurenine metabolism as a common mediator of genetic and environmental impacts in major depressive disorder: the serotonin hypothesis revisited 40 years later. Isr. J. Psychiatry Relat. Sci. 47 (2010), 56–63.
163. Pacher, P., Nivorozhkin, A., Szabo, C., Therapeutic effects of xanthine oxidase inhibitors: renaissance half a century after the discovery of allopurinol. Pharmacol. Rev. 58 (2006), 87–114.
164. Pantouris, G., Serys, M., Yuasa, H.J., Ball, H.J., Mowat, C.G., Human indoleamine 2,3-dioxygenase-2 has substrate specificity and inhibition characteristics distinct from those of indoleamine 2,3-dioxygenase-1. Amino Acids 46 (2014), 2155–2163.
165. Patki, G., Lau, Y.S., Melatonin protects against neurobehavioral and mitochondrial deficits in a chronic mouse model of Parkinson's disease. Pharmacol. Biochem. Behav. 99 (2011), 704–711.
166. Pellicciari, R., Amori, L., Costantino, G., Giordani, A., Macchiarulo, A., Mattoli, L., Pevarello, P., Speciale, C., Varasi, M., Modulation of the kynurine pathway of tryptophan metabolism in search for neuroprotective agents. Focus on kynurenine-3-hydroxylase. Adv. Exp. Med. Biol. 527 (2003), 621–628.
167. Perkins, M.N., Stone, T.W., An iontophoretic investigation of the actions of convulsant kynurenines and their interaction with the endogenous excitant quinolinic acid. Brain Res. 247 (1982), 184–187.
168. Pierozan, P., Zamoner, A., Soska, A.K., Silvestrin, R.B., Loureiro, S.O., Heimfarth, L., Mello E Souza, T., Wajner, M., Pessoa-Pureur, R., Acute intrastriatal administration of quinolinic acid provokes hyperphosphorylation of cytoskeletal intermediate filament proteins in astrocytes and neurons of rats. Exp. Neurol. 224 (2010), 188–196.
169. Pierozan, P., Ferreira, F., de Lima, B.O., Pessoa-Pureur, R., Quinolinic acid induces disrupts cytoskeletal homeostasis in striatal neurons. Protective role of astrocyte-neuron interaction. J. Neurosci. Res. 93 (2015), 268–284.
170. Pilotte, L., Larrieu, P., Stroobant, V., Colau, D., Dolusic, E., Frederick, R., De Plaen, E., Uyttenhove, C., Wouters, J., Masereel, B., Van den Eynde, B.J., Reversal of tumoral immune resistance by inhibition of tryptophan 2,3-dioxygenase. Proc. Natl. Acad. Sci. U. S. A. 109 (2012), 2497–2502.
171. Pisar, M., Forrest, C.M., Khalil, O.S., Mcnair, K., Vincenten, M.C., Qasem, S., Darlington, L.G., Stone, T.W., Modified neocortical and cerebellar protein expression and morphology in adult rats following prenatal inhibition of the kynurenine pathway. Brain Res. 1576 (2014), 1–17.
172. Powers, M.B., Asmundson, G.J., Smits, J.A., Exercise for mood and anxiety disorders: the state-of-the science. Cogn. Behav. Ther. 44 (2015), 237–239.
173. Prescott, C., Weeks, A.M., Staley, K.J., Partin, K.M., Kynurenic acid has a dual action on AMPA receptor responses. Neurosci. Lett. 402 (2006), 108–112.
174. Qian, F., Villella, J., Wallace, P.K., Mhawech-Fauceglia, P., Tario, J.D. Jr., Andrews, C., Matsuzaki, J., Valmori, D., Ayyoub, M., Frederick, P.J., Beck, A., Liao, J., Cheney, R., Moysich, K., Lele, S., Shrikant, P., Old, L.J., Odunsi, K., Efficacy of levo-1-methyl tryptophan and dextro-1-methyl tryptophan in reversing indoleamine-2,3-dioxygenase-mediated arrest of T-cell proliferation in human epithelial ovarian cancer. Cancer Res. 69 (2009), 5498–5504.
175. Radant, A.D., Bowdle, T.A., Cowley, D.S., Kharasch, E.D., Roy-Byrne, P.P., Does ketamine-mediated N-methyl-D-aspartate receptor antagonism cause schizophrenia-like oculomotor abnormalities?. Neuropsychopharmacology 19 (1998), 434–444.
176. Raison, C.L., Broadwell, S.D., Borisov, A.S., Manatunga, A.K., Capuron, L., Woolwine, B.J., Jacobson, I.M., Nemeroff, C.B., Miller, A.H., Depressive symptoms and viral clearance in patients receiving interferon-alpha and ribavirin for hepatitis C. Brain Behav. Immun. 19 (2005), 23–27.
177. Raison, C.L., Dantzer, R., Kelley, K.W., Lawson, M.A., Woolwine, B.J., Vogt, G., Spivey, J.R., Saito, K., Miller, A.H., CSF concentrations of brain tryptophan and kynurenines during immune stimulation with IFN-alpha: relationship to CNS immune responses and depression. Mol. Psychiatry 15 (2010), 393–403.
178. Raison, C.L., Rutherford, R.E., Woolwine, B.J., Shuo, C., Schettler, P., Drake, D.F., Haroon, E., Miller, A.H., A randomized controlled trial of the tumor necrosis factor antagonist infliximab for treatment-resistant depression: the role of baseline inflammatory biomarkers. JAMA Psychiatry 70 (2013), 31–41.
179. Rajda, C., Majlath, Z., Pukoli, D., Vecsei, L., Kynurenines and multiple sclerosis: the dialogue between the immune system and the central nervous system. Int. J. Mol. Sci. 16 (2015), 18270–18282.
180. Rejdak, K., Bartosik-Psujek, H., Dobosz, B., Kocki, T., Grieb, P., Giovannoni, G., Turski, W.A., Stelmasiak, Z., Decreased level of kynurenic acid in cerebrospinal fluid of relapsing-onset multiple sclerosis patients. Neurosci. Lett. 331 (2002), 63–65.
181. Rejdak, K., Petzold, A., Kocki, T., Kurzepa, J., Grieb, P., Turski, W.A., Stelmasiak, Z., Astrocytic activation in relation to inflammatory markers during clinical exacerbation of relapsing-remitting multiple sclerosis. J. Neural Transm. 114 (2007), 1011–1015.
182. Reus, G.Z., Jansen, K., Titus, S., Carvalho, A.F., Gabbay, V., Quevedo, J., Kynurenine pathway dysfunction in the pathophysiology and treatment of depression: evidences from animal and human studies. J. Psychiatr. Res. 68 (2015), 316–328.
183. Rohrig, U.F., Majjigapu, S.R., Vogel, P., Zoete, V., Michielin, O., Challenges in the discovery of indoleamine 2,3-dioxygenase 1 (IDO1) inhibitors. J. Med. Chem., 2015, 10.1021/acs.jmedchem.5b00326.
184. Rossi, F., Valentina, C., Garavaglia, S., Sathyasaikumar, K.V., Schwarcz, R., Kojima, S., Okuwaki, K., Ono, S., Kajii, Y., Rizzi, M., Crystal structure-based selective targeting of the pyridoxal 5'-phosphate dependent enzyme kynurenine aminotransferase II for cognitive enhancement. J. Med. Chem. 53 (2010), 5684–5689.
185. Rozsa, E., Robotka, H., Vecsei, L., Toldi, J., The Janus-face kynurenic acid. J. Neural Transm. 115 (2008), 1087–1091.
186. Rung, J.P., Carlsson, A., Ryden Markinhuhta, K., Carlsson, M.L., (+)-MK-801 induced social withdrawal in rats; a model for negative symptoms of schizophrenia. Prog. Neuropsychopharmacol. Biol. Psychiatry 29 (2005), 827–832.
187. Saito, K., Crowley, J.S., Markey, S.P., Heyes, M.P., A mechanism for increased quinolinic acid formation following acute systemic immune stimulation. J. Biol. Chem. 268 (1993), 15496–15503.
188. Salter, M., Hazelwood, R., Pogson, C.I., Iyer, R., Madge, D.J., Jones, H.T., Cooper, B.R., Cox, R.F., Wang, C.M., Wiard, R.P., The effects of an inhibitor of tryptophan 2,3-dioxygenase and a combined inhibitor of tryptophan 2,3-dioxygenase and 5-HT reuptake in the rat. Neuropharmacology 34 (1995), 217–227.
189. Sauve, A.A., Wolberger, C., Schramm, V.L., Boeke, J.D., The biochemistry of sirtuins. Annu. Rev. Biochem. 75 (2006), 435–465.
190. Schuck, P.F., Tonin, A., da Costa Ferreira, G., Viegas, C.M., Latini, A., Duval Wannmacher, C.M., de Souza Wyse, A.T., Dutra-Filho, C.S., Wajner, M., Kynurenines impair energy metabolism in rat cerebral cortex. Cell. Mol. Neurobiol. 27 (2007), 147–160.
191. Schwarcz, R., Rassoulpour, A., Wu, H.Q., Medoff, D., Tamminga, C.A., Roberts, R.C., Increased cortical kynurenate content in schizophrenia. Biol. Psychiatry 50 (2001), 521–530.
192. Schwarcz, R., Bruno, J.P., Muchowski, P.J., Wu, H.-Q., Kynurenines in the mammalian brain: when physiology meets pathology. Nat. Rev. Neurosci. 13 (2012), 465–477.
193. Schwarcz, R., Bruno, J.P., Muchowski, P.J., Wu, H.Q., Kynurenines in the mammalian brain: when physiology meets pathology. Nat. Rev. Neurosci. 13 (2012), 465–477.
194. Schwieler, L., Erhardt, S., Erhardt, C., Engberg, G., Prostaglandin-mediated control of rat brain kynurenic acid synthesis–opposite actions by COX-1 and COX-2 isoforms. J. Neural Transm. (Vienna) 112 (2005), 863–872.
195. Schwieler, L., Larsson, M.K., Skogh, E., Kegel, M.E., Orhan, F., Abdelmoaty, S., Finn, A., Bhat, M., Samuelsson, M., Lundberg, K., Dahl, M.L., Sellgren, C., Schuppe-Koistinen, I., Svensson, C., Erhardt, S., Engberg, G., Increased levels of IL-6 in the cerebrospinal fluid of patients with chronic schizophrenia–significance for activation of the kynurenine pathway. J. Psychiatry Neurosci. 40 (2015), 126–133.
196. Sharma, R., Mcmillan, C.R., Tenn, C.C., Niles, L.P., Physiological neuroprotection by melatonin in a 6-hydroxydopamine model of Parkinson's disease. Brain Res. 1068 (2006), 230–236.
197. Silva-Adaya, D., Perez-De La Cruz, V., Villeda-Hernandez, J., Carrillo-Mora, P., Gonzalez-Herrera, I.G., Garcia, E., Colin-Barenque, L., Pedraza-Chaverri, J., Santamaria, A., Protective effect of L-kynurenine and probenecid on 6-hydroxydopamine-induced striatal toxicity in rats: implications of modulating kynurenate as a protective strategy. Neurotoxicol. Teratol. 33 (2011), 303–312.
198. Smith, R.S., The macrophage theory of depression. Med. Hypotheses 35 (1991), 298–306.
199. Sominsky, L., Fuller, E.A., Bondarenko, E., Ong, L.K., Averell, L., Nalivaiko, E., Dunkley, P.R., Dickson, P.W., Hodgson, D.M., Functional programming of the autonomic nervous system by early life immune exposure: implications for anxiety. PLoS One, 8, 2013, e57700.
200. Spitzer, C., Barnow, S., Volzke, H., Wallaschofski, H., John, U., Freyberger, H.J., Lowe, B., Grabe, H.J., Association of posttraumatic stress disorder with low-grade elevation of C-reactive protein: evidence from the general population. J. Psychiatr. Res. 44 (2010), 15–21.
201. St'astny, F., Hinoi, E., Ogita, K., Yoneda, Y., Ferrous iron modulates quinolinate-mediated [3H]MK-801 binding to rat brain synaptic membranes in the presence of glycine and spermidine. Neurosci. Lett. 262 (1999), 105–108.
202. Stark, J.L., Avitsur, R., Padgett, D.A., Campbell, K.A., Beck, F.M., Sheridan, J.F., Social stress induces glucocorticoid resistance in macrophages. Am. J. Physiol. Regul. Integr. Comp. Physiol. 280 (2001), R1799–R1805.
203. Stone, T.W., Neuropharmacology of quinolinic and kynurenic acids. Pharmacol. Rev. 45 (1993), 309–379.
204. Sundaram, G., Brew, B.J., Jones, S.P., Adams, S., Lim, C.K., Guillemin, G.J., Quinolinic acid toxicity on oligodendroglial cells: relevance for multiple sclerosis and therapeutic strategies. J. Neuroinflamm., 11, 2014, 204.
205. Swartz, K.J., During, M.J., Freese, A., Beal, M.F., Cerebral synthesis and release of kynurenic acid: an endogenous antagonist of excitatory amino acid receptors. J. Neurosci. 10 (1990), 2965–2973.
206. Szalardy, L., Zadori, D., Toldi, J., Fulop, F., Klivenyi, P., Vecsei, L., Manipulating kynurenic acid levels in the brain – on the edge between neuroprotection and cognitive dysfunction. Curr. Top. Med. Chem. 12 (2012), 1797–1806.
207. Tan, L., Yu, J.T., Tan, L., The kynurenine pathway in neurodegenerative diseases: mechanistic and therapeutic considerations. J. Neurol. Sci. 323 (2012), 1–8.
208. Tavares, R.G., Tasca, C.I., Santos, C.E., Alves, L.B., Porciuncula, L.O., Emanuelli, T., Souza, D.O., Quinolinic acid stimulates synaptosomal glutamate release and inhibits glutamate uptake into astrocytes. Neurochem. Int. 40 (2002), 621–627.
209. Ting, K.K., Brew, B., Guillemin, G., The involvement of astrocytes and kynurenine pathway in Alzheimer's disease. Neurotox. Res. 12 (2007), 247–262.
210. Vaidya, V.A., Marek, G.J., Aghajanian, G.K., Duman, R.S., 5-HT2A receptor-mediated regulation of brain-derived neurotrophic factor mRNA in the hippocampus and the neocortex. J. Neurosci. 17 (1997), 2785–2795.
211. van Erp, T.G., Saleh, P.A., Huttunen, M., Lonnqvist, J., Kaprio, J., Salonen, O., Valanne, L., Poutanen, V.P., Standertskjold-Nordenstam, C.G., Cannon, T.D., Hippocampal volumes in schizophrenic twins. Arch. Gen. Psychiatry 61 (2004), 346–353.
212. Varga, D., Heredi, J., Kanvasi, Z., Ruszka, M., Kis, Z., Ono, E., Iwamori, N., Iwamori, T., Takakuwa, H., Vecsei, L., Toldi, J., Gellert, L., Systemic L-Kynurenine sulfate administration disrupts object recognition memory, alters open field behavior and decreases c-Fos immunopositivity in C57Bl/6 mice. Front. Behav. Neurosci., 9, 2015, 157.
213. Vecsei, L., Szalardy, L., Fulop, F., Toldi, J., Kynurenines in the CNS: recent advances and new questions. Nat. Rev. Drug Discov. 12 (2013), 64–82.
214. Verstraelen, P., Pintelon, I., Nuydens, R., Cornelissen, F., Meert, T., Timmermans, J.P., Pharmacological characterization of cultivated neuronal networks: relevance to synaptogenesis and synaptic connectivity. Cell. Mol. Neurobiol. 34 (2014), 757–776.
215. Vogelzangs, N., Beekman, A.T., de Jonge, P., Penninx, B.W., Anxiety disorders and inflammation in a large adult cohort. Transl. Psychiatry, 3, 2013, e249.
216. Wang, J., Simonavicius, N., Wu, X., Swaminath, G., Reagan, J., Tian, H., Ling, L., Kynurenic acid as a ligand for orphan G protein-coupled receptor GPR35. J. Biol. Chem. 281 (2006), 22021–22028.
217. Webster, M.J., Knable, M.B., O'Grady, J., Orthmann, J., Weickert, C.S., Regional specificity of brain glucocorticoid receptor mRNA alterations in subjects with schizophrenia and mood disorders. Mol. Psychiatry 7 (2002), 985–994 924.
218. Welch, A.N., Badawy, A.A., Tryptophan pyrrolase in haem regulation. Experiments with administered haematin and the relationship between the haem saturation of tryptophan pyrrolase and the activity of 5-aminolaevulinate synthase in rat liver. Biochem. J. 192 (1980), 403–410.
219. Wonodi, I., Stine, O.C., Sathyasaikumar, K.V., Roberts, R.C., Mitchell, B.D., Hong, L.E., Kajii, Y., Thaker, G.K., Schwarcz, R., Downregulated kynurenine 3-monooxygenase gene expression and enzyme activity in schizophrenia and genetic association with schizophrenia endophenotypes. Arch. Gen. Psychiatry 68 (2011), 665–674.
220. Wszelaki, N., Melzig, M.F., Research on an in vitro cell system for testing the neurotoxicity of kynurenine pathway metabolites. Pharmazie 66 (2011), 899–903.
221. Wu, W., Nicolazzo, J.A., Wen, L., Chung, R., Stankovic, R., Bao, S.S., Lim, C.K., Brew, B.J., Cullen, K.M., Guillemin, G.J., Expression of tryptophan 2,3-dioxygenase and production of kynurenine pathway metabolites in triple transgenic mice and human Alzheimer's disease brain. PLoS One, 8, 2013, e59749.
222. Xie, W., Cai, L., Yu, Y., Gao, L., Xiao, L., He, Q., Ren, Z., Liu, Y., Activation of brain indoleamine 2,3-dioxygenase contributes to epilepsy-associated depressive-like behavior in rats with chronic temporal lobe epilepsy. J. Neuroinflamm., 11, 2014, 41.
223. Ying, W., NAD+ and NADH in cellular functions and cell death. Front. Biosci. 11 (2006), 3129–3148.
224. Zadori, D., Klivenyi, P., Plangar, I., Toldi, J., Vecsei, L., Endogenous neuroprotection in chronic neurodegenerative disorders: with particular regard to the kynurenines. J. Cell. Mol. Med. 15 (2011), 701–717.
225. Zadori, D., Szalardy, L., Toldi, J., Fulop, F., Klivenyi, P., Vecsei, L., Some molecular mechanisms of dopaminergic and glutamatergic dysfunctioning in Parkinson's disease. J. Neural Transm. 120 (2013), 673–681.
226. Zhang, L., Guadarrama, L., Corona-Morales, A.A., Vega-Gonzalez, A., Rocha, L., Escobar, A., Rats subjected to extended L-tryptophan restriction during early postnatal stage exhibit anxious-depressive features and structural changes. J. Neuropathol. Exp. Neurol. 65 (2006), 562–570.
227. Zinger, A., Barcia, C., Herrero, M.T., Guillemin, G.J., The involvement of neuroinflammation and kynurenine pathway in Parkinson's disease. Park. Dis., 2011, 2011, 716859.
228. Zwilling, D., Huang, S.Y., Sathyasaikumar, K.V., Notarangelo, F.M., Guidetti, P., Wu, H.Q., Lee, J., Truong, J., Andrews-Zwilling, Y., Hsieh, E.W., Louie, J.Y., Wu, T., Scearce-Levie, K., Patrick, C., Adame, A., Giorgini, F., Moussaoui, S., Laue, G., Rassoulpour, A., Flik, G., Huang, Y., Muchowski, J.M., Masliah, E., Schwarcz, R., Muchowski, P.J., Kynurenine 3-monooxygenase inhibition in blood ameliorates neurodegeneration. Cell 145 (2011), 863–874.
229. 1-Methyl-D-tryptophan and docetaxel in treating patients with metastatic solid tumors. http://clinicaltrials.gov/show/NCT01191216; (accessed 18.09.15.).